FIELD: biotechnology.
SUBTANCE: invention relates to the field of biotechnology. A group of inventions is described, including the use of a compound carrying a glycomodified Fc fragment as an immunosuppression inhibitor in the treatment of cancer-associated immunosuppression and a pharmaceutical composition for the treatment of cancer-associated immunosuppression containing an effective amount of (i) a compound carrying a glycomodified Fc fragment and an effective amount of (ii) an inhibitor protein inhibitor immune checkpoint. In one embodiment, a compound carrying a glycomodified Fc fragment is a glycomodified antibody.
EFFECT: invention expands the arsenal of drugs for the treatment of immunosuppression associated with cancer.
13 cl, 45 dwg, 18 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMHRII BINDING COMPOUNDS FOR PREVENTING OR TREATING CANCER | 2018 |
|
RU2816523C2 |
| RECOMBINANT YEAST CELLS PRODUCING POLYLACTIC ACID AND THEIR USE | 2016 |
|
RU2758138C2 |
| ANTIBODIES TO BTN3A AND THEIR USE IN THE TREATMENT OF CANCER OR INFECTIOUS DISEASES | 2019 |
|
RU2800726C2 |
| AMHRII BINDING COMPOUNDS FOR THE PREVENTION OR TREATMENT OF LUNG CANCERS | 2018 |
|
RU2797506C2 |
| BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| VARIANTS OF ACID ALPHA-GLUCOSIDASE AND THEIR USE | 2017 |
|
RU2780410C2 |
| GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
| ISOLATED HUMAN CD45RC ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, CELL, PHARMACEUTICAL COMPOSITION, USE THEREOF, IN VITRO METHOD OF DETECTING hCD45RC | 2019 |
|
RU2826421C2 |
| IMMUNE TOLERANCE INDUCING ANTIBODIES, INDUCED LYMPHOCYTES AND THERAPEUTIC AGENT/METHOD OF CELL THERAPY USING INDUCED LYMPHOCYTES | 2019 |
|
RU2816592C2 |
